Yin Tong, Liu Jingyu, Wu Yue, Peng Xiaobo, Hao Zhibin, Zhang Jingxi, Zhan Xianbao
Department of Oncology, Changhai Hospital, Naval Medical University, Shanghai, China.
Sci Technol Adv Mater. 2025 Jul 25;26(1):2537000. doi: 10.1080/14686996.2025.2537000. eCollection 2025.
Current tumor therapies face significant limitations such as hypoxic microenvironments, systemic toxicity, and immunosuppression. Thylakoid-based nanomaterials strategically integrate the structural-functional properties of natural biological components with the versatility of nanotechnology. These biomaterials have garnered substantial scientific interest due to their promising therapeutic potential in oncology. Thylakoids perform essential biological functions including solar energy absorption, photolytic oxygen generation, and operation of photosynthetic electron transport chains. Harnessing thylakoid-specific photochemical properties through nanoscale hybridization offers an innovative paradigm for developing multifunctional platforms in oncotherapy. This review summarizes current challenges in tumor therapy and the advantages of thylakoid-based nanomaterials in addressing these limitations. We further examine recent advances in the engineering design of thylakoid-based nanomaterials and their therapeutic applications. Finally, we discuss existing challenges and future prospects in this field.
当前的肿瘤治疗面临着诸如缺氧微环境、全身毒性和免疫抑制等重大限制。基于类囊体的纳米材料将天然生物成分的结构功能特性与纳米技术的多功能性进行了战略性整合。由于这些生物材料在肿瘤学中具有广阔的治疗潜力,因此已引起了科学界的广泛关注。类囊体执行着重要的生物学功能,包括太阳能吸收、光解产氧以及光合电子传递链的运行。通过纳米级杂交利用类囊体特有的光化学性质,为开发肿瘤治疗中的多功能平台提供了一种创新模式。本综述总结了肿瘤治疗中的当前挑战以及基于类囊体的纳米材料在克服这些限制方面的优势。我们进一步研究了基于类囊体的纳米材料的工程设计及其治疗应用的最新进展。最后,我们讨论了该领域现有的挑战和未来前景。
Sci Technol Adv Mater. 2025-7-25
Acta Biomater. 2025-7-1
Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2025
Arch Ital Urol Androl. 2025-6-30
Nanomedicine (Lond). 2025-7
Regen Biomater. 2025-6-11
J Nanobiotechnology. 2024-11-27
Exploration (Beijing). 2024-3-15
Front Plant Sci. 2024-4-17
Sci Technol Adv Mater. 2024-2-7
Nat Comput Sci. 2023-12